Identifying the real-world challenges of dysplasia surveillance in inflammatory bowel disease: a retrospective cohort study in a tertiary health network

被引:2
|
作者
Elford, Alexander T. T. [1 ,2 ,4 ]
Hirsch, Ryan [1 ]
McKay, Owen M. M. [1 ]
Browne, Mitchell [1 ]
Moore, Gregory T. T. [1 ,3 ]
Bell, Sally [1 ,3 ]
Swan, Michael [1 ,3 ]
机构
[1] Monash Hlth, Melbourne, Vic, Australia
[2] Univ Melbourne, Melbourne, Vic, Australia
[3] Monash Univ, Melbourne, Vic, Australia
[4] Gastroenterol Dept, 300 Grattan St, Parkville, Vic 3050, Australia
关键词
inflammatory bowel disease; dysplasia; dye chromoendoscopy; PRIMARY SCLEROSING CHOLANGITIS; WHITE-LIGHT ENDOSCOPY; ULCERATIVE-COLITIS; COLORECTAL-CANCER; TARGETED BIOPSIES; RISK; COLONOSCOPY; NEOPLASIA; CHROMOENDOSCOPY; CARCINOMA;
D O I
10.1111/imj.16102
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundDysplasia surveillance in inflammatory bowel disease (IBD) is often suboptimal and deviates from guidelines. AimsTo assess dysplasia surveillance behaviours and adherence to guidelines amongst a large tertiary teaching health network with a specialised IBD unit to identify areas where dysplasia surveillance could be improved. MethodsA retrospective audit of IBD surveillance colonoscopy practice over an 18-month period was performed using the Provation Endoscopy Database and the hospital's primary sclerosing cholangitis database. ResultsThe audit identified 115 dysplasia surveillance colonoscopies. A total of 37% of index dysplasia colonoscopies were outside recommended guidelines. A total of 10% had inadequate bowel preparation and only 40% had excellent bowel preparation. A total of 28% of patients underwent dye-based chromoendoscopy and 69% underwent high-definition white-light endoscopy. Dye chromoendoscopy was more likely to be used by IBD specialists than interventional endoscopists (P = 0.008) and other endoscopists (P = 0.004). Only IBD specialists and interventional endoscopists used dye chromoendoscopy. Dysplasia or colorectal cancer was detected in 3.4% of the colonoscopies. Overall, the several dysplasia examinations were lower than expected. ConclusionsDysplasia surveillance in the IBD population remains an area of improvement given the current national guidelines. IBD specialists are more likely to perform dye chromoendoscopy than other endoscopists/gastroenterologists. Dysplasia rates in this real-world contemporary setting are less than expected in historical studies and may represent improvements in IBD management principles and medications.
引用
收藏
页码:96 / 103
页数:8
相关论文
共 50 条
  • [31] Real-world experience with subcutaneous infliximab: broadening treatment strategies for inflammatory bowel disease
    Smith, Philip J.
    Fumery, Mathurin
    Leong, Rupert W.
    Novak, Kerri
    Dignass, Axel
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2023, 19 (09) : 1143 - 1156
  • [32] Is cervical dysplasia a major concern in females with inflammatory bowel disease? A Spanish retrospective study
    Fernandez, Lorena Jara
    Ferrer, Juan Angel
    Calle, Jose Lazaro Perez
    Serrano, Pilar Lopez
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2024, 116 (05) : 292 - 292
  • [33] Impact of Biological Therapies and Tofacitinib on Real-world Work Impairment in Inflammatory Bowel Disease Patients: A Prospective Study
    Thomas, Pepijn W. A.
    den Broeder, Nathan
    Derikx, Monique
    Kievit, Wietske
    West, Rachel L.
    Russel, Maurice G. V. M.
    Jansen, Jeroen M.
    Romkens, Tessa E. H.
    Hoentjen, Frank
    INFLAMMATORY BOWEL DISEASES, 2022, 28 (12) : 1813 - 1820
  • [34] Patients' real-world experience with inflammatory bowel disease: A cross-sectional survey in tertiary care centres from the GETAID group *
    Nachury, Maria
    Bouhnik, Yoram
    Serrero, Melanie
    Filippi, Jerome
    Roblin, Xavier
    Kirchgesner, Julien
    Bouguen, Guillaume
    Franchimont, Denis
    Savoye, Guillaume
    Buisson, Anthony
    Louis, Edouard
    Nancey, Stephane
    Abitbol, Vered
    Reimund, Jean-Marie
    DeWit, Olivier
    Vuitton, Lucine
    Matthieu, Nicolas
    Peyrin-Biroulet, Laurent
    Gilletta, Cyrielle
    Tadbiri, Sara
    Allez, Matthieu
    Viennot, Stephanie
    Bourreille, Arnaud
    Laharie, David
    Amiot, Aurelien
    DIGESTIVE AND LIVER DISEASE, 2021, 53 (04) : 434 - 441
  • [35] Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease
    Schreiber, Stefan
    Dignass, Axel
    Peyrin-Biroulet, Laurent
    Hather, Greg
    Demuth, Dirk
    Mosli, Mahmoud
    Curtis, Rebecca
    Khalid, Javaria Mona
    Loftus, Edward Vincent, Jr.
    JOURNAL OF GASTROENTEROLOGY, 2018, 53 (09) : 1048 - 1064
  • [36] The Clinical Course of Bowel Urgency Severity Among Patients with Inflammatory Bowel Disease-A Real-World Study
    Lewis, James D.
    Gibble, Theresa Hunter
    Shan, Mingyang
    Zhou, Xian
    Naegeli, April N.
    Dawwas, Ghadeer K.
    DRUGS-REAL WORLD OUTCOMES, 2024, 11 (03) : 403 - 412
  • [37] Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: A real-world cohort analysis
    Kumar, Peeyush
    Vuyyuru, Sudheer K.
    Kante, Bhaskar
    Kedia, Saurabh
    Sahu, Pabitra
    Ranjan, Mukesh Kumar
    Mundhra, Sandeep
    Golla, Rithvik
    Kumar, Mukesh
    Virmani, Shubi
    Gupta, Anvita
    Yadav, Nidhi
    Makharia, Govind
    Ahuja, Vineet
    INDIAN JOURNAL OF GASTROENTEROLOGY, 2022, 41 (05) : 446 - 455
  • [38] Comparative Effectiveness of Vedolizumab vs. Infliximab Induction Therapy in Ulcerative Colitis: Experience of a Real-World Cohort at a Tertiary Inflammatory Bowel Disease Center
    Allamneni, Chaitanya
    Venkata, Krishna
    Yun, Huifeng
    Xie, Fenglong
    DeLoach, Lindsey
    Malik, Talha A.
    GASTROENTEROLOGY RESEARCH, 2018, 11 (01) : 41 - 45
  • [39] Real-world experience of vedolizumab use in Colombian patients with inflammatory bowel disease--EXVEDOCOL
    Parra, Viviana
    Cifuentes, Sandra
    Avendano, Sandra
    de Leon, Enrique Ponce
    Florez, Cristian
    Reyes, Gustavo
    Puentes, Fabian
    Ballesteros, Manuel
    Nunez, Edilberto
    Gomez, Federico
    Marquez, Juan Ricardo
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2024, 47 (08): : 858 - 866
  • [40] Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: A real-world cohort analysis
    Peeyush Kumar
    Sudheer K. Vuyyuru
    Bhaskar Kante
    Saurabh Kedia
    Pabitra Sahu
    Mukesh Kumar Ranjan
    Sandeep Mundhra
    Rithvik Golla
    Mukesh Kumar
    Shubi Virmani
    Anvita Gupta
    Nidhi Yadav
    Govind Makharia
    Vineet Ahuja
    Indian Journal of Gastroenterology, 2022, 41 : 446 - 455